HC Wainwright Reaffirms “Buy” Rating for Dianthus Therapeutics (NASDAQ:DNTH)
HC Wainwright reaffirmed their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a report issued on Monday, Benzinga reports. They currently have a $40.00 target price on the stock. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q3 2024 earnings at ($0.53) EPS, Q4 2024 earnings at ($0.73) EPS, FY2024 earnings […]
More Stories
NIL (Name, Image, and Likeness): Top 20 Highest-Paid College Athletes
The NCAA (National Collegiate Athletic Association) is a US-based government body that regulates the rules of sports in colleges and...
Porsche Recalls More than 173,500 Vehicles for Rear-Camera Malfunction
By Rob Sabo Porsche Cars North America, Inc. has issued a recall of 173,538 vehicles manufactured during the past six...
Chief Justice Roberts Says Americans Continue to Admire the Constitution
By Matthew Vadum Chief Justice John Roberts said on Dec. 31 that as the United States prepares to celebrate its...
US Rings in New Year as the World Welcomes 2026
By Troy Myers and Joseph Lord The East Coast rang in 2026 as the clock struck midnight on New Year’s...
500 Illegal Immigrants Arrested in Minnesota, 1,000 Immigration-Fraud Cases Investigated: DHS Official
By Janice Hisle As additional investigators surge to fraud-plagued Minnesota, federal agents have already arrested 500 illegal immigrants and probed...
Oil Glut Pushes Prices Down, Easing Inflation in 2025—What’s Ahead
By Panos Mourdoukoutas Rising global inventories weighed on oil markets in 2025, crushing prices and helping push headline inflation lower....